KRAS/p53-mutant CRC, compared with CRC with mutations in one or none of these genes, acquires high metastatic ability and anticancer drug resistance, such as cetuximab resistance, which confers poor outcomes in patients 5. The gene discussed is KRAS; the disease is colorectal carcinoma.